86 related articles for article (PubMed ID: 23324659)
1. An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity.
Borrego P; Calado R; Marcelino JM; Pereira P; Quintas A; Barroso H; Taveira N
AIDS; 2013 Apr; 27(7):1081-90. PubMed ID: 23324659
[TBL] [Abstract][Full Text] [Related]
2. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
3. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
5. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
6. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
7. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
Lohrengel S; Hermann F; Hagmann I; Oberwinkler H; Scrivano L; Hoffmann C; von Laer D; Dittmar MT
J Virol; 2005 Aug; 79(16):10237-46. PubMed ID: 16051817
[TBL] [Abstract][Full Text] [Related]
8. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
[TBL] [Abstract][Full Text] [Related]
9. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
Dwyer JJ; Wilson KL; Davison DK; Freel SA; Seedorff JE; Wring SA; Tvermoes NA; Matthews TJ; Greenberg ML; Delmedico MK
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12772-7. PubMed ID: 17640899
[TBL] [Abstract][Full Text] [Related]
10. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
[TBL] [Abstract][Full Text] [Related]
11. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
[TBL] [Abstract][Full Text] [Related]
12. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
13. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
[TBL] [Abstract][Full Text] [Related]
14. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
[TBL] [Abstract][Full Text] [Related]
16. Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates.
Vincent N; Kone A; Chanut B; Lucht F; Genin C; Malvoisin E
AIDS; 2008 Oct; 22(16):2075-85. PubMed ID: 18832871
[TBL] [Abstract][Full Text] [Related]
17. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli.
Pusch O; Kalyanaraman R; Tucker LD; Wells JM; Ramratnam B; Boden D
AIDS; 2006 Oct; 20(15):1917-22. PubMed ID: 16988512
[TBL] [Abstract][Full Text] [Related]
18. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
19. Site-directed enzyme-linked immunosorbent assay with a synthetic simian immunodeficiency virus SIVmac peptide identifying antibodies against the HIV-2 transmembrane glycoprotein.
Norrby E; Chiodi F; Whalley A; Parks E; Nauclér A; Costa CM; Torstensson R; Biberfeld G
AIDS; 1989 Jan; 3(1):17-20. PubMed ID: 2469436
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]